Universite Dé Lorraine

Institut National De La Sante Et De La Recherche Medicale

Université Henri Poincaré-Nancy I

Bristol-myers Squibb Compnay

Novo Nordisk A/s

Bristol-myers Squibb

Aphp (Assistance Publique-Hôpitaux De Paris)

Inotrem

Sorbonne Université

Universite Paris Cité

Université Henri Poincaré Nancy 1

Aphp

Inserm

Sebastien Gibot

Marc Derive

Paola Panina

Gilbert Faure

Nadia Passini

Hafid Ait-Oufella

Amir Boufenzer

Nicolas Danchin

Tabasomme Simon

Marie Nathalie Kolopp-Sarda

Marie-Christine Bene

Pietro Di Lucia

Bruno Levy

Pierre-Edouard Bollaert

A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

Methods and kits for predicting the risk of having a cardiovascular disease or event

A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.

Therapeutic TREM-1 peptides

The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.

Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof

The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases

A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterized by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.

Polypeptide The present invention relates to polypeptides fragments derived from the protein TLT-1 have been isolated and are useful in pharmaceutical preparations used for the treatment of inflammatory conditions such as sepsis.

The present invention concerns a method of diagnosing disease of bacterial or fungal origin in a subject, which method comprises the step of measuring the level of Strem-1 in a biological sample obtained from said subject.

Method of diagnosing infectious disease by measuring the level of soluble TREM-1 in a sample

Therapeutic peptides and method

Growing community of inventors

Vandoeuvre les Nancy, France

Sebastien Gibot